CCM
RAPT

CAAS Capital Management’s RAPT Therapeutics RAPT Stock Holding History

CAAS Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,060
Closed -$4.08M – 1086
2021
Q2 		$4.08M Buy
+16,060
New +$3M 0.07% 278
2020
Q4 		– Sell
-3,061
Closed -$789K – 908
2020
Q3 		$789K Buy
+3,061
New +$679K 0.02% 359

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAAS Capital Management's RAPT Position: Q3 2021 in Review

CAAS Capital Management sold out of RAPT Therapeutics (RAPT) in Q3 2021, closing a stake of 16,060 shares — an estimated $4.08M sold.

CAAS Capital Management first reported a position in RAPT in Q3 2020 and held it in 2 quarters. The position peaked at $4.08M in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q3 2021.

  • CAAS Capital Management reported no remaining RAPT Therapeutics position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 16,060 RAPT Therapeutics shares in Q3 2021, an estimated $4.08M.
  • CAAS Capital Management first reported a position in RAPT Therapeutics in Q3 2020 and held it in 2 quarters.
  • CAAS Capital Management's RAPT Therapeutics position peaked at $4.08M in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.